Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3861-3880 of 3,900 trials

Blood Cancer Treatment: Ciltacabtagene Autoleucel

We are studying the effects of a new infusion treatment for patients with blood cancers. The trial compares different ways of administering the treatment to see which is more effective and safe.

Newly Diagnosed Multiple MyelomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Dilated Cardiomyopathy: AZD4063 Study

We are investigating the safety and effects of AZD4063 in adults with dilated cardiomyopathy due to a specific PLN gene mutation. The study aims to see how the drug works in the body and its impact on PLN mRNA levels.

Dilated Cardiomyopathy>2 yearsSafety phase (I)CardiologyInternal Medicine

Deuruxolitinib: Safety Study in Healthy Adults

We are testing a new medication to see how safe it is and how the body reacts to it in healthy adults. This study helps us understand its potential for future treatments.

Alopecia Areata6-12 monthsSafety phase (I)AllergologyInfectious DiseasesRheumatology

MK-4082: A Study in Healthy Volunteers

We are testing a new medication called MK-4082 in healthy individuals. This study aims to understand its safety and how it works in the body.

Weight Management3-6 monthsSafety phase (I)EndocrinologyInternal Medicine

Cold-Induced Urticaria: GTX-B001 Treatment

We are testing a new treatment for people with cold-induced urticaria to see how well it is tolerated and its effects on symptoms. The study includes both healthy volunteers and patients.

Cold-Induced Urticaria1-2 yearsSafety phase (I)AllergologyDermatology

Open-Heart Surgery: Parasternal Block for Pain Relief

We are studying whether a special nerve block helps reduce pain and opioid use in patients recovering from open-heart surgery. This trial aims to improve recovery experiences for these patients.

Postoperative Pain Management>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal MedicineOtolaryngology

RO7504109: Immune Cell Study

We are investigating how the new treatment RO7504109 affects immune cells in healthy individuals. This research may help us learn more about its potential uses in the future.

Healthy Participants6-12 monthsSafety phase (I)AllergologyDermatologyInternal MedicineOphthalmologyOtolaryngologyPediatricsPsychiatry

CIT-013 for Inflammatory Mediated Immune Diseases

We are studying how a new treatment, CIT-013, spreads in the body of patients with inflammatory mediated immune diseases. We also want to learn about its safety and how the body handles it.

Inflammatory Mediated Immune Diseases≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Skin Immune Response: SYX-5219 Treatment

We are investigating how SYX-5219 affects immune responses in the skin. This study aims to understand its potential benefits for skin-related conditions.

Atopic Dermatitis3-6 monthsSafety phase (I)Dermatology

NTX-1955: CO2 Challenge Study

We are testing a new treatment called NTX-1955 in healthy participants to see how it affects carbon dioxide levels in the body. This research may help us understand its potential uses in health.

Generalized Anxiety Disorder1-2 yearsSafety phase (I)Psychiatry

ACD856: Safety Study in Healthy Volunteers

We are testing a new medication called ACD856 to see how safe it is and how it affects the body. This study involves healthy participants to help us understand its effects better.

DepressionCognitive DysfunctionAlzheimer’s Disease3-6 monthsSafety phase (I)NeurologyPsychiatry

Cenerimod: Bioavailability Study in Healthy Men

We are evaluating how well the body absorbs cenerimod in healthy male participants. This study aims to gather important information for future treatments.

Healthy Participants3-6 monthsSafety phase (I)

Cabergoline for Episodic Migraine Relief

We are studying whether cabergoline can help reduce the frequency and severity of migraines in people with episodic migraine. Participants will receive either cabergoline or a placebo to compare effects.

Episodic Migraine6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology

Survodutide: Comparing Two Formulations

We are studying how two different formulations of survodutide are absorbed by healthy people. This research may help improve future treatments using this medication.

Healthy Volunteers6-12 monthsSafety phase (I)

Drug Interaction Study: Carbamazepine and PF-07248144

We are investigating how multiple doses of Carbamazepine affect the way the body processes another medication, PF-07248144. This study aims to improve our understanding of drug interactions.

Locally Advanced or Metastatic ER+/HER2- Breast Cancer3-6 monthsSafety phase (I)Internal MedicineOncology

Psoriasis Treatment: CKD-704 vs. Skyrizi®

We are comparing a new biosimilar treatment for psoriasis with the approved Skyrizi® to see how safe it is and how well it works in healthy adults.

Moderately to Severely Active Crohn’s DiseaseModerate-to-Severe Plaque PsoriasisActive Psoriatic Arthritis6-12 monthsSafety phase (I)DermatologyGastroenterologyInfectious DiseasesRheumatology

Alzheimer’s Disease: MTX46943 Study

We are investigating a new compound to see if it is safe and effective for treating Alzheimer’s disease and other neurological disorders. This study looks at how the drug is absorbed and processed in the body.

Alzheimer's Disease6-12 monthsSafety phase (I)Internal MedicineNeurology

Pain Measurement: Nefopam and Oxycodone Study

We are exploring new test methods to measure pain in individuals using nefopam and oxycodone. This research aims to improve how we assess pain relief with these medications.

Chronic Pain6-12 monthsSafety phase (I)Internal MedicineNeurology

Psoriasis: Investigational Skin Products

We are assessing the safety and effects of new products on skin affected by psoriasis. This study aims to understand how these products may help improve skin health.

Plaque Psoriasis6-12 monthsSafety phase (I)AllergologyDermatology

Chronic Constipation: Lecicarbon® Treatment Study

We are evaluating the safety and tolerability of long-term treatment with Lecicarbon® for people with chronic constipation. This study aims to understand how well patients can manage this treatment over time.

Chronic Constipation1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterology